Merck’s Pulmonary Arterial Hypertension Drug Sotatercept Phase III Clinical Success
ADC评论
October 13, 2022
Merck announced that the Phase III STELLAR clinical study of sotatercept in pulmonary arterial hypertension (PAH) achieved positive top-line results, meeting the primary endpoint and
